Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96D09
UPID:
GASP2_HUMAN
Alternative names:
-
Alternative UPACC:
Q96D09; D3DXA0; Q8NAB4
Background:
G-protein coupled receptor-associated sorting protein 2 plays a crucial role in the regulation of G-protein coupled receptors (GPCRs), which are key in cellular communication and signal transduction. Its involvement in the intricate processes that govern cellular responses makes it a focal point of research.
Therapeutic significance:
The protein is linked to Deafness, X-linked, 7, a congenital disorder characterized by bilateral mixed or conductive hearing loss, which may progress in some patients. This association highlights its potential as a target for therapeutic intervention in hearing loss and related dysmorphisms.